BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure UpdateCompany outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure.
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing SignalThe flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks.
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness FormulaRetirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial InvestorStrategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches.
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic PlatformLAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront operations and direct-to-consumer (DTC) marketing footprint for its flagship cognitive performance line, MyndSystem™.
